Skip to main content
. 2019 Apr 18;20(Suppl 4):152. doi: 10.1186/s12859-019-2688-6

Fig. 5.

Fig. 5

Evaluation of decompTumor2Sig. Absolute differences between the exposures to 15 signatures predicted by decompTumor2Sig for 44 out of 435 tumors of different cancer types, and the respective exposures computed with pmsignature using the full dataset